Osimertinib plus capivasertib for advanced lung cancer with certain gene changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted therapies for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has progressed after taking osimertinib. The combination may help control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced non-small cell lung cancer that is not squamous and cannot be cured with surgery or radiation.
- Your cancer must have an EGFR mutation (exon 19 deletion or L858R) and you must have been treated with osimertinib as your first therapy for metastatic disease.
- Your cancer must have grown while on osimertinib, and you must not have had immunotherapy for metastatic disease.
- You must provide a tumor tissue sample taken after progression on osimertinib that shows changes in PIK3CA, AKT1, or PTEN genes.
- You must have at least one measurable tumor that has not been irradiated or biopsied during screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.